Blueweave
Global Anticancer Drugs Market

Special Offer: SPECIAL OFFER: Avail Attractive Year End Discount!

Global Anticancer Drugs Market, By Drug Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy), By Indication (Lung Cancer, Breast Cancer, Stomach Cancer, Colorectal Cancer, Prostate Cancer, Others), By Dosage Form (Solid, Liquid, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), By Region (North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle-East & Africa (MEA) Trend Analysis, Competitive Market Share & Forecast, 2017-2027

  • Published Date: August 2021
  • Report ID: BWC2129
  • Available Format: PDF
  • Page: 200

Report Overview

The global anticancer drugs market is growing at a high rate due to the increasing prevalence of various types of cancer and expanding research and development activities for improving and increasing the effectiveness of anticancer drugs.

The global anticancer drugs market was worth USD 112.3 billion in 2020 and is further projected to reach USD 175.9 billion by the year 2027, growing at a CAGR of 6.9% in the forecast period. The market is growing at a high rate due to the increasing prevalence of various types of cancer. Worldwide, cancer has been estimated to cause 19.3 million cases in 2020 and 10 million deaths.Furthermore, the increased effort to improve and enhance the effectiveness of anticancer drugs is also driving the growth of the global anticancer drugs market.

Anticancer Drugs Market

Source: BlueWeave Consulting

Global Anticancer Drugs Market- Overview

Anticancer drugs are medications which are effective in the treatment of malignant and cancerous diseases. They are also known as antineoplastic drugs. Currently, the most common cancer therapy is Celgene's Revlimid (lenalidomide), which has proven to be very successful in treating multiple myeloma due to its ability to improve immune responses and decelerate tumor growth.Other common anticancer drugs are Altretamine, Temozolomid, Mechlorethamine, Procarbazine, Carmustine.

Global Anticancer Drugs Market Forecast and Trends

Growth Drivers

Increasing Prevalence of Various Types of Cancer

The prevalence of cancer is increasing at a very high rate. It has been estimated that there were more than 19.3 million cases and 10 million deaths worldwide due to cancer.The International Agency for Research on Cancer (IARC) estimates that 17.0 million new cases of cancer were diagnosed in 2018 and 9.5 million cancer deaths occurred globally. Furthermore, the global burden of cancer is expected to rise to 27.5 million new cases and 16.3 million cancer deaths by 2040. Because of the high prevalence of cancer, there is a surge in demand for anticancer drugs for the treatment of various types of cancer, which in turn is propelling the global anticancer drugs market forward.

Expanding R&D Activities Favoringthe Development of Anticancer Drugs

Cancer is a very advanced and complex disease, so its treatment necessitates the use of multifunctional drugs that are effective in controlling the disease.Therefore, the pharmaceutical and biotechnology companies constantly engage themselves in R & D activities for advancing anticancer drugs. For instance, research institutes are working towards the development of hybrid anticancer drugs. Hybrid compounds have more than a single target which proves to be more effective in destroying cancer cells. Anticancer drugs market is expected to flourish in upcoming years, as a result of such research activities

Restraints

Adverse Side Effects of Anticancer Drugs

Despite high demand for anticancer drugs, the adverse long-term side effects they have on patients cannot be ignored.The cancer patients receiving targeted therapy, chemotherapy, or other types of therapies often experience side effects such as diarrhea, fatigue, edema (swelling), nausea, vomiting, etc. In addition to bruising and bleeding, cancer drugs can increase the risk of infection and breathlessness.In order to minimize these effects, the researchers are working hard, but they are still far from succeeding.Thus, the side effects of cancer treatment may is impeding the growth of the anticancer drugs market.

Impact of COVID-19 on Global Anticancer Drugs Market

With the sudden onset of COVID-19, hospitals were faced with unprecedented challenges.The COVID-19-induced pandemic has been a significant drain on health care resources as well as professionals.Due to this, the diagnosis and treatment of many other diseases were postponed or put on hold. However, this situation presented significant growth opportunities for the global anticancer drug market.This is because the cancer patientsavoided visiting hospitals facilities as they were most susceptible to transmission of COVID-19. This in turn proliferated the overall market growth because of their reliance on anticancer drugs to control cancer cells.

Global Anticancer Drugs Market - By Drug Class

Based on drug class, the global anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, and hormonal drugs. Due to the high adoption of targeted therapy for cancer treatment, the targeted drug segment accounts for the largest market share.Compared to chemotherapy, target therapy has fewer side effects because it doesn't attack healthy cells and prompts the body's immune system to attack the cancer cells. Because of this, R&D activities in anticancer drug research are more closely focused on developing targeted drugs.

Global Anticancer Drugs Market - By Indication

Based on indications, the global anticancer drugs market is segmented into lung cancer, breast cancer, stomach cancer, colorectal cancer, prostate cancer, and others. The breast cancer segment accounts for the largest share of this market since it is the most prevalent type of cancer, surpassing lung cancer. According to the WHO, 2.3 million women diagnosed with breast cancer in 2020 and it led to 685,000 deaths worldwide. Furthermore, the increasing awareness of breast cancer is also driving the demand for diagnostic tests, which further drives the demand for anticancer drugs.

Global Anticancer Drugs Market - Regional Insights

Geographically, the global anticancer drugs market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle-East & Africa. Among these regions, North America dominates the market due to the high prevalence of cancer in countries like the US and Canada and the increasing diagnostic tests for cancer types like breast cancer. According to estimates, there are 1.9 million cancer cases in Northern America of which breast cancer, lung cancer, and prostate cancer affect a significant percentage of the population. As a result, the demand for anticancer drugs is flourishing at a high rate in this region.

Regional Insights

Source: BlueWeave Consulting

Competitive Landscape

The leading market players in the global anticancer drugs market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., Amgen, Takeda Oncology Drugs Ltd., GlaxoSmithKline, Sanofi, Celgene Corporation, Boehringer Ingelheim GmbH, Teva Pharmaceuticals, Eli Lilly and Company, Millennium Pharmaceuticals, Kolaz Biotech, and other prominent players.

The industry participants invest heavily in the R&D activities for product approvals and launches to stay ahead in the competition. They also offer a wide range of products to various geographical locations to expand their market revenue share. Furthermore, the adoption of competitive strategies like partnerships, mergers, collaborations, joint ventures is also very prominent in this market.

Recent Development

  • In July 2021, GenFleet Therapeutics, a Chinese biotech company, and Insilico Medicine, a Hongkong-based biotechnology company, announced their strategic partnership for advancing novel therapies and addressing unmet medical needs in cancer therapeutics.
  • In February 2021, Cend Therapeutics, a US-based biotechnology company, and Qilu Pharmaceutical, a Chinese Pharmaceutical Company, announced their collaboration and license agreement to commercialize Cend’s cancer treatment to China.

Scope of the Report

Attributes

Details

Years Considered

Historical data – 2017-2020

Base Year – 2020

Forecast – 2021 – 2027

Facts Covered

Revenue in USD Million

Market Coverage

U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Japan, South Korea, China, India, UAE, South Africa, Saudi Arabia

Product Service/Segmentation

By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Region

Key Players

Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., Amgen, Takeda Oncology Drugs Ltd., GlaxoSmithKline, Sanofi, Celgene Corporation, Boehringer Ingelheim GmbH, Teva Pharmaceuticals, Eli Lilly and Company, Millennium Pharmaceuticals, Kolaz Biotech, and other prominent players.

 

By Drug Class

  • Cytotoxic Drugs
  1. Alkylating Agents
  2. Antimetabolites
  3. Others
  • Targeted Drugs
  1. Monoclonal Antibodies
  2. Others
  • Hormonal Drugs

By Therapy

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

By Indication

  • Lung Cancer
  • Breast Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

By Dosage Form

  • Solid
  1. Tablets
  2. Capsules
  • Liquid
  • Injectable
  1. Prefilled Syringes
  2. others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Latin America (LATAM)
  • Middle-East & Africa (MEA)

 

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Research Methodology
    1. Qualitative Research
    2. Methodology
    3. Regional Split of Primary & Secondary Research
    4. Secondary Research
    5. Primary Research
      1. Breakdown of Primary Research Respondents, By Region
        1. Breakdown of Primary Research Respondents, By Industry Participants
    6. Market Size Estimation
    7. Assumptions for the Study
    8. Market Breakdown & Data Triangulation
  3. Executive Summary
  4. Industry Insight and Growth Strategy
    1. Value Chain Analysis
    2. DROC Analysis
      1. Market Drivers
        1. Increasing Prevalence of Various Types Of Cancer
        2. Expanding R&D Activities In The Development Of Anticancer Drugs
      2. Market Restraints
        1. Adverse Side Effects of Anticancer Drugs
      3. Market Challenges
        1. High Price of Anticancer Drugs
      4. Market Opportunity
        1. Increasing Adoption of Target Therapies for Cancer Treatment
        2. Growing Demand for Injectables
    3. Recent Developments
    4. Porter’s Five Forces Analysis
      1. Bargaining Power of Buyers
      2. Bargaining Power of Suppliers
      3. Intensity of Rivalry
      4. Threat of New Entrants
      5. Threat of Substitutes
  5. Global Anticancer Drugs Market Overview
    1. Market Estimates & Forecast by Value, 2017-2027
    2. Market Share & Forecast
      1. By Drug Class
        1. Cytotoxic Drugs
          1. Alkylating Agents
          2. Antimetabolites
          3. Others
        2. Targeted Drugs
          1. Monoclonal Antibodies
          2. Others
        3. Hormonal Drugs
      2. By Therapy
        1. Chemotherapy
        2. Targeted Therapy
        3. Immunotherapy
      3. By Indication
        1. Lung Cancer
        2. Breast Cancer
        3. Stomach Cancer
        4. Colorectal Cancer
        5. Prostate Cancer
        6. Others
      4. By Dosage Form
        1. Solid
          1. Tablets
          2. Capsules
        2. Liquid
        3. Injectable
          1. Prefilled Syringes
          2. others
      5. By Distribution Channel
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online
        4. Others
      6. By Region
        1. North America
        2. Europe
        3. Asia-Pacific (APAC)
        4. Latin America (LATAM)
        5. Middle-East & Africa (MEA)
  6. North America Anticancer Drugs Market Overview
    1. Market Size and Forecast
      1. By Value (USD Million), 2017-2027
    2. Market Share and Forecast
      1. By Drug Class
      2. By Therapy
      3. By Indication
      4. By Dosage Form
      5. By Distribution Channel
      6. By Country
        1. U.S.
        2. Canada
  7. Europe Anticancer Drugs Market Overview
    1. Market Size and Forecast
      1. By Value (USD Million), 2017-2027
    2. Market Share and Forecast
      1. By Drug Class
      2. By Therapy
      3. By Indication
      4. By Dosage Form
      5. By Distribution Channel
      6. By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Netherlands
        7. Rest of Europe
  8. APAC Anticancer Drugs Market Overview
    1. Market Size and Forecast
      1. By Value (USD Million), 2017-2027
    2. Market Share and Forecast
      1. By Drug Class
      2. By Therapy
      3. By Indication
      4. By Dosage Form
      5. By Distribution Channel
      6. By Country
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Rest of APAC
  9. LATAM Anticancer Drugs Market Overview
    1. Market Size and Forecast
      1. By Value (USD Million), 2017-2027
    2. Market Share and Forecast
      1. By Drug Class
      2. By Therapy
      3. By Indication
      4. By Dosage Form
      5. By Distribution Channel
      6. By Country
        1. Mexico
        2. Brazil
        3. Rest of LATAM
  10. MEA Anticancer Drugs Market Overview
    1. Market Size and Forecast
      1. By Value (USD Million), 2017-2027
    2. Market Share and Forecast
      1. By Drug Class
      2. By Therapy
      3. By Indication
      4. By Dosage Form
      5. By Distribution Channel
      6. By Country
        1. Saudi Arabia
        2. UAE
        3. South Africa
        4. Rest of Europe
  11. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Market Share / Ranking Analysis (2020)
    3. Competitive Benchmarking, By Operating Parameters
  12. Impact of COVID-19 on Global Anticancer Drugs Market
  13. Company Profiles (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
    1. Johnson & Johnson
    2. F. Hoffmann-La Roche Ltd.
    3. Pfizer Inc.
    4. Novartis AG
    5. Merck & Co. Inc.
    6. Bristol-Myers Squibb Company
    7. AstraZeneca PLC
    8. Astellas Pharma Inc.
    9. AbbVie Inc.
    10. Amgen
    11. Takeda Oncology Drugs Ltd.
    12. GlaxoSmithKline
    13. Sanofi
    14. Celgene Corporation
    15. Boehringer Ingelheim GmbH
    16. Teva Pharmaceuticals
    17. Eli Lilly and Company
    18. Millennium Pharmaceuticals
    19. Kolaz Biotech
    20. Other Prominent Players
  14. Key Strategic Recommendations

 

 

List of Figures

 

Figure 1: Global Anticancer Drugs Devices Segmentation

 

Figure 2: Global Anticancer Drugs Devices Market Value Chain Analysis,

 

Figure 3: Company Market Share Analysis, 2020

 

Figure 4: Global Anticancer Drugs Devices Market Size, By Value (USD Million), 2017-2027

 

Figure 5: Global Anticancer Drugs Devices Market Share (%), By Drug Class, By Value, 2017-2027

 

Figure 6: Global Anticancer Drugs Devices Market Share (%), By Therapy, By Value, 2017-2027

 

Figure 7: Global Anticancer Drugs Devices Market Share (%), By Indication, By Value, 2017-2027

 

Figure 8: Global Anticancer Drugs Devices Market Share (%), By Dosage Form, By Value, 2017-2027

 

Figure 9: Global Anticancer Drugs Devices Market Share (%), By Distribution Channel, By Value, 2017-2027

 

Figure 10: Global Anticancer Drugs Devices Market Share (%), By Region, By Value, 2017-2027

 

Figure 11: North America Anticancer Drugs Devices Market Size, By Value (USD Million), 2017-2027

 

Figure 12: North America Anticancer Drugs Devices Market Share (%), By Drug Class, By Value, 2017-2027

 

Figure 13: North America Anticancer Drugs Devices Market Share (%), By Therapy, By Value, 2017-2027

 

Figure 14: North America Anticancer Drugs Devices Market Share (%), By Indication, By Value, 2017-2027

 

Figure 15: North America Anticancer Drugs Devices Market Share (%), By Dosage Form, By Value, 2017-2027

 

Figure 16: North America Anticancer Drugs Devices Market Share (%), By Distribution Channel, By Value, 2017-2027

 

Figure 17: North America Anticancer Drugs Devices Market Share (%), By Country, By Value, 2017-2027

 

Figure 18: Europe Anticancer Drugs Devices Market Size, By Value (USD Million), 2017-2027

 

Figure 19: Europe Anticancer Drugs Devices Market Share (%), By Drug Class, By Value, 2017-2027

 

Figure 20: Europe Anticancer Drugs Devices Market Share (%), By Therapy, By Value, 2017-2027

 

Figure 21: Europe Anticancer Drugs Devices Market Share (%), By Indication, By Value, 2017-2027

 

Figure 22: Europe Anticancer Drugs Devices Market Share (%), By Dosage Form, By Value, 2017-2027

 

Figure 23: Europe Anticancer Drugs Devices Market Share (%), by Distribution Channel, By Value, 2017-2027

 

Figure 24: Europe Anticancer Drugs Devices Market Share (%), By Country, By Value, 2017-2027

 

Figure 25: Asia-Pacific Anticancer Drugs Devices Market Size, By Value (USD Million), 2017-2027

 

Figure 26: Asia-Pacific Anticancer Drugs Devices Market Share (%), By Drug Class, By Value, 2017-2027

 

Figure 27: Asia-Pacific Anticancer Drugs Devices Market Share (%), By Therapy, By Value, 2017-2027

 

Figure 28: Asia-Pacific Anticancer Drugs Devices Market Share (%), By Indication, By Value, 2017-2027

 

Figure 29: Asia-Pacific Anticancer Drugs Devices Market Share (%), By Dosage Form, By Value, 2017-2027

 

Figure 30: Asia-Pacific Anticancer Drugs Devices Market Share (%), By Distribution Channel, By Value, 2017-2027

 

Figure 31: Asia-Pacific Anticancer Drugs Devices Market Share (%), By Country, By Value, 2017-2027

 

Figure 32: Latin America Anticancer Drugs Devices Market Size, By Value (USD Million), 2017-2027

 

Figure 33: Latin America Anticancer Drugs Devices Market Share (%), By Drug Class, By Value, 2017-2027

 

Figure 34: Latin America Anticancer Drugs Devices Market Share (%), By Therapy, By Value, 2017-2027

 

Figure 35: Latin America Anticancer Drugs Devices Market Share (%), By Indication, By Value, 2017-2027

 

Figure 36: Latin America Anticancer Drugs Devices Market Share (%), By Dosage Form, By Value, 2017-2027

 

Figure 37: Latin America Anticancer Drugs Devices Market Share (%), By Distribution Channel, By Value, 2017-2027

 

Figure 38: Latin America Anticancer Drugs Devices Market Share (%), By Country, By Value, 2017-2027

 

Figure 39: Middle East & Africa Anticancer Drugs Devices Market Size, By Value (USD Million), 2017-2027

 

Figure 40: Middle East & Africa Anticancer Drugs Devices Market Share (%), By Drug Class, By Value, 2017-2027

 

Figure 41: Middle East & Africa Anticancer Drugs Devices Market Share (%), By Therapy, By Value, 2017-2027

 

Figure 42: Middle East & Africa Anticancer Drugs Devices Market Share (%), By Indication, By Value, 2017-2027

 

Figure 43: Middle East & Africa Anticancer Drugs Devices Market Share (%), By Dosage Form, By Value, 2017-2027

 

Figure 44: Middle East & Africa Anticancer Drugs Devices Market Share (%), By Distribution Channel, By Value, 2017-2027

 

Figure 45: Middle East & Africa Anticancer Drugs Devices Market Share (%), By Region, By Value, 2017-2027

 

 

 

List of Tables

 

Table 1: Global Anticancer Drugs Devices Design Size, By Drug Class, By Value, 2017-2027

 

Table 2: Global Anticancer Drugs Devices Design Size, By Therapy, By Value (USD Million), 2017-2027

 

Table 3: Global Anticancer Drugs Devices Design Size, By Indication, By Value (USD Million), 2017-2027

 

Table 4: Global Anticancer Drugs Devices Design Size, By Dosage Form, By Value (USD Million), 2017-2027

 

Table 5: Global Anticancer Drugs Devices Design Size, By Distribution Channel, By Value (USD Million), 2017-2027

 

Table 6: Global Anticancer Drugs Devices Design Size, By Region, By Value (USD Million), 2017-2027

 

Table 7: North America Anticancer Drugs Devices Market Size, By Drug Class, By Value (USD Million), 2017-2027

 

Table 8: North America Anticancer Drugs Devices Market Size, By Therapy, By Value (USD Million), 2017-2027

 

Table 9: North America Anticancer Drugs Devices Market Size, By Indication, By Value (USD Million), 2017-2027

 

Table 10: North America Anticancer Drugs Devices Market Size, By Dosage Form, By Value (USD Million), 2017-2027

 

Table 11: North America Anticancer Drugs Devices Market Size, By Distribution Channel, By Value (USD Million), 2017-2027,

 

Table 12: Europe Anticancer Drugs Devices Market Size, By Drug Class, By Value (USD Million), 2017-2027

 

Table 13: Europe Anticancer Drugs Devices Market Size, By Therapy, By Value (USD Million), 2017-2027

 

Table 14: Europe Anticancer Drugs Devices Market Size, By Indication, By Value (USD Million), 2017-2027

 

Table 15: Europe Anticancer Drugs Devices Market Size, By Dosage Form, By Value (USD Million), 2017-2027

 

Table 16: Europe Anticancer Drugs Devices Market Size, By Distribution Channel, By Value (USD Million), 2017-2027

 

Table 17: the Asia-Pacific Anticancer Drugs Devices Market Size, By Drug Class, By Value (USD Million), 2017-2027

 

Table 18: the Asia-Pacific Anticancer Drugs Devices Market Size, By Therapy, By Value (USD Million), 2017-2027

 

Table 19: the Asia-Pacific Anticancer Drugs Devices Market Size, By Indication, By Value (USD Million), 2017-2027

 

Table 20: the Asia-Pacific Anticancer Drugs Devices Market Size, By Dosage Form, By Value (USD Million), 2017-2027

 

Table 21: the Asia-Pacific Anticancer Drugs Devices Market Size, By Distribution Channel, By Value (USD Million), 2017-2027

 

Table 22: Latin America Anticancer Drugs Devices Market Size, By Drug Class, By Value (USD Million), 2017-2027

 

Table 23: Latin America Anticancer Drugs Devices Market Size, By Therapy, By Value (USD Million), 2017-2027

 

Table 24: Latin America Anticancer Drugs Devices Market Size, By Indication, By Value (USD Million), 2017-2027

 

Table 25: Latin America Anticancer Drugs Devices Market Size, By Dosage Form, By Value (USD Million), 2017-2027

 

Table 26: Latin America Anticancer Drugs Devices Market Size, By Distribution Channel, By Value (USD Million), 2017-2027

 

Table 27: The Middle-East & Africa Anticancer Drugs Devices Market Size, By Drug Class, By Value (USD Million), 2017-2027

 

Table 28: The Middle-East & Africa Anticancer Drugs Devices Market Size, By Therapy, By Value (USD Million), 2017-2027

 

Table 29: The Middle-East & Africa Anticancer Drugs Devices Market Size, By Indication, By Value (USD Million), 2017-2027

 

Table 30: The Middle-East & Africa Anticancer Drugs Devices Market Size, By Dosage Form, By Value (USD Million), 2017-2027

 

Table 31: The Middle-East & Africa Anticancer Drugs Devices Market Size, By Distribution Channel, By Value (USD Million), 2017-2027

 

Table 32: Johnson & Johnson Financial Analysis

Table 33: Johnson & Johnson Business Overview

Table 34: F. Hoffmann-La Roche Ltd.Financial Analysis

Table 35: F. Hoffmann-La Roche Ltd.Business Overview

Table 36: Pfizer Inc.Financial Analysis

Table 37: Pfizer Inc. Business Overview

Table 38: Novartis AGFinancial Analysis

Table 39: Novartis AG Business Overview

Table 40: Merck & Co. Inc. Financial Analysis

Table 41: Merck & Co. Inc.Business Overview

Table 42: Bristol-Myers Squibb Company Financial Analysis

Table 43: Bristol-Myers Squibb Company Business Overview

Table 44: AstraZeneca PLC Financial Analysis

Table 45: AstraZeneca PLC Business Overview

Table 46: Astellas Pharma Inc. Financial Analysis

Table 47: Astellas Pharma Inc. Business Overview

Table 48: AbbVie Inc.Financial Analysis

Table 49: AbbVie Inc.Business Overview

Table 50: Amgen Financial Analysis

Table 51: Amgen Business Overview

Table 52: Takeda Oncology Drugs Ltd. Financial Analysis

Table 53: Takeda Oncology Drugs Ltd.Financial Analysis

Table 52: GlaxoSmithKline Financial Analysis

Table 53: GlaxoSmithKline Business Overview

Table 54: Sanofi Financial Analysis

Table 55: Sanofi Business Overview

Table 56: Celgene Corporation Financial Analysis

Table 57: Celgene Corporation Business Overview

Table 58: Boehringer Ingelheim GmbH Financial Analysis

Table 59: Boehringer Ingelheim GmbH Business Overview

Table 60: Teva Pharmaceuticals Financial Analysis

Table 61: Teva Pharmaceuticals Business Overview

Table 62: Eli Lilly and Company Financial Analysis

Table 63: Eli Lilly and Company Business Overview

Table 64: Millennium PharmaceuticalsFinancial Analysis

Table 65: Millennium Pharmaceuticals Business Overview

Table 66: Kolaz Biotech Financial Analysis

Table 67: Kolaz Biotech Business Overview

Market Segmentation

By Drug Class

  • Cytotoxic Drugs
  1. Alkylating Agents
  2. Antimetabolites
  3. Others
  • Targeted Drugs
  1. Monoclonal Antibodies
  2. Others
  • Hormonal Drugs

By Therapy

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

By Indication

  • Lung Cancer
  • Breast Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

By Dosage Form

  • Solid
  1. Tablets
  2. Capsules
  • Liquid
  • Injectable
  1. Prefilled Syringes
  2. others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Latin America (LATAM)
  • Middle-East & Africa (MEA)
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: The global anticancer drugs market reached USD 112.3 billion in 2020.
Ans: The major factors driving the growth of the global anticancer drugs market are; increasing prevalence of various types of cancer and expanding r&d activities in the development of anticancer drugs.
Ans: The key players in the global anticancer drugs market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., Amgen, Takeda Oncology Drugs Ltd., GlaxoSmithKline, Sanofi, Celgene Corporation, Boehringer Ingelheim GmbH, Teva Pharmaceuticals, Eli Lilly and Company, Millennium Pharmaceuticals, Kolaz Biotech, and other prominent players.
Ans: The targeted therapy segment accounted for the largest share in the global anticancer drugs market.
Ans: North America has the largest share in the global anticancer drugs market.